Dynavax Technologies Co. (NASDAQ:DVAX) Stock Holdings Lessened by Jane Street Group LLC

Jane Street Group LLC reduced its holdings in shares of Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 42.4% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 446,185 shares of the biopharmaceutical company's stock after selling 328,208 shares during the period. Jane Street Group LLC owned approximately 0.34% of Dynavax Technologies worth $4,971,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently bought and sold shares of DVAX. Millennium Management LLC purchased a new stake in shares of Dynavax Technologies in the second quarter valued at about $17,615,000. Great Point Partners LLC raised its position in Dynavax Technologies by 87.7% during the second quarter. Great Point Partners LLC now owns 2,374,000 shares of the biopharmaceutical company's stock worth $26,660,000 after acquiring an additional 1,109,080 shares during the last quarter. Assenagon Asset Management S.A. acquired a new position in Dynavax Technologies during the third quarter worth about $8,291,000. PDT Partners LLC acquired a new position in Dynavax Technologies during the third quarter worth about $3,967,000. Finally, Mizuho Markets Americas LLC raised its position in Dynavax Technologies by 37.9% during the second quarter. Mizuho Markets Americas LLC now owns 1,175,107 shares of the biopharmaceutical company's stock worth $13,196,000 after acquiring an additional 323,050 shares during the last quarter. 96.96% of the stock is owned by hedge funds and other institutional investors.

Dynavax Technologies Stock Up 0.4 %

DVAX traded up $0.05 during trading hours on Tuesday, reaching $12.90. 2,385,036 shares of the stock traded hands, compared to its average volume of 2,111,915. Dynavax Technologies Co. has a fifty-two week low of $9.74 and a fifty-two week high of $15.01. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34. The company has a market cap of $1.70 billion, a price-to-earnings ratio of 99.15 and a beta of 1.33. The firm's fifty day simple moving average is $12.06 and its two-hundred day simple moving average is $11.49.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a "buy" rating and issued a $29.00 price objective on shares of Dynavax Technologies in a research report on Friday, November 8th.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.